Development of an Arthroscopically Compatible Polymer Additive Layer Manufacture Technique

Simon W Partridge¹,*; Matthew J Benning¹; Matthew J German² and Kenneth W Dalgarno¹.

¹School of Mechanical and Systems Engineering, Newcastle University, Newcastle upon-Tyne, UK.

²Centre for Oral Health Research, School of Dental Sciences, Newcastle University, Newcastle upon Tyne, UK.

*Corresponding author: simon.partridge@ncl.ac.uk.

1 Abstract

This paper describes a proof of concept study designed to evaluate the potential for an
in-vivo 3D printing route to support minimally invasive repair of the musculoskeletal
system. The study uses a photocurable material to additively manufacture in-situ a
model implant, and demonstrates that this can be achieved effectively within a clinically
relevant timescale. The approach has the potential to be applied with a wide range of
light curable materials, and with development could be applied to create functionally
gradient structures in-vivo.

Keywords: 3d printing, arthroscope, additive manufacture, minimally invasive
2 Introduction

The use of minimally invasive techniques for surgical interventions offers clear advantages to both the healthcare system and to the patient. Procedures are generally quicker, the degree of surgical insult is lower, which means that hospital stays and rehabilitation periods are shorter, which in turn offers a faster return to work and society for the patient. For the musculoskeletal system arthroscopic techniques are commonly used to enable examination, biopsy, debridement, and microfracture. In order to seek to repair the musculoskeletal system with minimal invasion, materials which can be injected into the body have been developed, notably cements for vertebroplasty and kyphoplasty procedures, and polymeric or particulate bone defect filling materials. More recently there has been interest in the arthroscopic delivery of osteochondral plugs to treat small joint defects, but this approach has not yet progressed to clinical adoption.

An alternative approach to bulk injection of a material is to use additive manufacturing to build up a 3D structure through the sequential formation and bonding of layers of material together. Previous work has shown that additive manufacture can, in principle, be used to fill joint defects, but has not yet been explored how this could be achieved minimally invasively. This approach offers potential advantages over existing injectable approaches as it could extend the range of materials which could be processed using a minimally invasive approach, by allowing the use of materials which cure or set more effectively in small volumes. In addition, the approach could be used to develop multi-material structures in order to provide a functionally gradient implant.
A potential methodology for clinical application is outlined schematically in figure 1. Preparation of the implant site would involve removing damaged tissue and providing a lining to the defect to temporarily isolate the site whilst development of the implant took place. Sequential deposition and in-situ curing, in this case through blue light, of material would then be used to develop the implant through additive manufacture in-vivo. Visible light is non-thermogenic, less damaging to the cells and provides curing at higher depths in comparison to UV light\textsuperscript{6,7}. Blue light curing is an attractive approach as it has been clinically applied widely in dentistry and with a higher depth penetration in comparison to violet light\textsuperscript{7-9}.

![Figure 1 – Arthroscopic In-vivo Manufacture. Envisaged process is (a) preparation and isolation of the defect site; (b) deposition and (c) in-situ curing of material, repeated to fill defect (d).](image)

The work presented in this paper describes a proof of concept study undertaken to understand if a blue light curable material could be effectively delivered arthroscopically
in order to fill a model osteochondral defect within a clinically useful timescale. HEMA (hydroxyethylmethacrylate) monomer was chosen as a model material for the study: it is a dental filler material with established blue light cure protocols, and well understood cure characteristics.

3 Materials and Methods

3.1 Materials and Preparation

Table 1 details the reagents used to create the HEMA solutions, and table 2 shows the constitution of the three solutions and the role of the different materials in the blue light cure system. Langer et al. (1999)\textsuperscript{10} used a 1% w/v. % in a 1:1 ratio of camphorquinone (CQ) to amine, however others such as Dewaele et al. (2009)\textsuperscript{11} have used a 0.5 w/v. % 1:1 ratio. To determine whether the concentration of components in these systems work with the mono methyl ether hydroquinone (MEHQ) inhibited HEMA monomer the w/v. % and ratio were investigated at these reported values. The solutions were prepared by weighing CQ and ethyl 4-(dimethylamino) benzoate (EDMAB) into an amber glass vial with black polytetrafluoroethylene (PTFE) faced rubber lined cap (fisher Scientific, 11309493). Using a pipette triethylene glycol dimethacrylate (TEGDMA) was then added until it constituted 0.5 mol% of HEMA into the solution. The solution was then mixed for 1 hour using an SRT6 Stuart\textsuperscript{®} tube roller (Bibby Scientific Ltd., Staffordshire, UK).
<table>
<thead>
<tr>
<th>Chemical</th>
<th>Acronym</th>
<th>MEHQ</th>
<th>mol%</th>
<th>Product number</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-Hydroxyethylmethacrylate</td>
<td>HEMA</td>
<td>≤250</td>
<td>97</td>
<td>128635</td>
<td>Monomer</td>
</tr>
<tr>
<td>Camphorquinone</td>
<td>CQ</td>
<td>0</td>
<td>-</td>
<td>21325</td>
<td>Photoinitiator</td>
</tr>
<tr>
<td>Ethyl 4-(dimethylamino) benzoate</td>
<td>EDMAB</td>
<td>0</td>
<td>-</td>
<td>E24905</td>
<td>Activator</td>
</tr>
<tr>
<td>Triethylene glycol dimethacrylate</td>
<td>TEGDMA</td>
<td>80–</td>
<td>95</td>
<td>261548</td>
<td>Cross-linker</td>
</tr>
</tbody>
</table>

Table 1: Chemicals used for the formulation of photocurable HEMA solutions. All reagents purchased from Sigma Aldrich (Poole, UK).

<table>
<thead>
<tr>
<th>HEMA Mol %</th>
<th>TEGDMA mol/HEMA mol%</th>
<th>Camphorquinone (w/v. %)</th>
<th>EDMAB (w/v. %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>96.5</td>
<td>0.5</td>
<td>1</td>
</tr>
<tr>
<td>B</td>
<td>96.5</td>
<td>0.5</td>
<td>1</td>
</tr>
<tr>
<td>C</td>
<td>96.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Table 2: Photocurable HEMA solutions compositions.

3.2 Materials Processing

3.2.1 Light Source

A Cree® XLamp® XP-E LED (royal blue) 450-465 nm (Cree Inc., North Carolina, USA) was used with an optical PMMA LED lens (LEDiL, FP11085, Salo, Finland). Power was supplied by a British Standards Tester PSM 3/2A 3 channel regulated DC power supply (BSI group, London, UK). The radius of the illumination spot was measured as 0.5 cm when it was 1 cm from the lens, and the LED was operated at 734 mA, which gave an estimated power output of 1000 mW/cm².
3.2.2 Mould and Photocuring Chamber

A two-part PTFE mould was fabricated to provide an array of model defects. The top part of the PTFE mould consisted of an array of nine holes 8 mm in diameter with a 2 mm deep counterbore of 40 mm diameter cut to act as a location feature for the photocuring chamber. The base part of the PTFE mould consisted of an array of pins 8 mm in diameter aligned to fit into the holes in the top part. Upon assembly, the wells were 8 mm in diameter with 6 mm depth (figure 1), chosen to be representative of small osteochondral defects.

Figure 1: Schematic diagram of the PTFE mould assembly (left) and image of the assembled PTFE mould (right).

The photocuring chamber consisted of a closed 3D printed PLA cylinder of 40 mm diameter with a central 3 mm hole for connecting the LED holder and a 5 mm hole for the wires and nitrogen inlet (figure 2). The PMMA LED lens was mounted to the XP-LED and attached to an aluminium column with Artic Silver®5 thermal paste (Visalia, CA, USA).
3.2.3 HEMA Polymerisation

The photochemical process of polymerisation depends on the transfer of reactive species generated by the photoinitiator CQ in response to blue light. The transfer of this reactive species from the CQ to the HEMA monomer is facilitated by the tertiary amide EDMAB and leads to propagation of the polymer chain. The presence of oxygen within this system absorbs the reactive species and thus retards initiation and propagation of the reaction \(^{12}\). In these experiments nitrogen gas was used to displace oxygen from the curing chamber to diminish oxygen inhibition of the photocuring process.

The intrinsic and extrinsic factors affecting curing efficiency are explained in detail in Leprince et al. (2013)\(^ {12}\). In terms of the exposure time the key factors include the formulation, volume, temperature and irradiance intensity. Ambient temperature was controlled by an air conditioning unit at 20°C.
In previous studies of blue light cure a range of blue light intensities have been used, ranging from $1 - 3000 \text{ mW/cm}^2$. The materials used in this study include the MEHQ inhibitor, which is added to dental formulations to provide shelf life. In order to ensure that the processing conditions would mitigate MEHQ inhibition, a relatively high light intensity of $1000\text{ mW/cm}^2$ was used.

The 10 mm distance of the LED to the maximal curing base was selected as this illuminated the build area effectively. From initial experiments, ~1 mm HEMA layers cured into a malleable disc with 1 minute exposure time, ergo controlled prolonged exposure time points were investigated.

To produce ~1 mm thick layers 50 μL of the HEMA solution was pipetted into a PTFE mould. The photocuring chamber with flowing nitrogen was then placed over the well as shown in figure 2 and the power supply activated to deliver 734 mA equating to 1000 mW/ cm² at the spot 10 mm from the lens. Therefore, HEMA exposure times were investigated between 1 and 10 minutes.

For multi-layered experiments this process was repeated, with no delay between the end of an exposure and the deposition of the material for the next layer, using formulation A, 734 mA, and an exposure time of 1 minute.

3.3 Material Characterisation

3.3.1 Fourier Transformed Infrared Spectroscopy (FTIR)

Solid material samples were analysed using an ATR-FTIR Perkin Elmer Spectrum 100 with PerkinElmer’s Spectrum™ v6 FT-IR software. Spectra were collected by cleaning the diamond/ZnSe crystal surface with acetone or 100% ethanol before and after use. The
machine was calibrated to background atmosphere prior to data collection. The base of the polymerised HEMA (polyHEMA) samples were then loaded onto the diamond/ZnSe ATR crystal detection area and locked in place using the pressure arm. All samples were polished using graded abrasive paper to ensure sufficient contact with the ATR crystal. Spectra were then recorded from 4000 cm$^{-1}$ to 650 cm$^{-1}$ with a resolution of 4 cm$^{-1}$ and a minimum of 32 scans per sample.

The multi-layered samples were bisected using a circular diamond blade. The samples were also polished to ensure contact with the ATR crystal. Measurements were taken centrally at the top and bottom of the samples (figure 3), with the ATR crystal adjacent to the top and bottom surfaces, and centrally in the middle of the samples halfway between the top and bottom measurements.

![Figure 3: Positioning of the ATR-FTIR detection crystal (red) on cross-sectioned polyHEMA cylinders (blue)](image)

The degree of conversion (DC) was calculated by comparing the vibrational band of the residual non-polymerised methacrylate C=C stretching mode at 1638 cm$^{-1}$ to the aromatic C-C stretching mode at 1710 cm$^{-1}$ used as an internal standard. The non-polymerised HEMA solution was used as a reference.
3.3.2 Imaging

The sectioned polyHEMA cylinders were imaged using a Leica M165FC with integrated LED spotlights. Images were acquired and processed using DFC310 FX camera Leica with the Application Suite (LAS) software (Leica Microsystems Heidelberg GMBH Germany).

Superficial heating of the sectioned polyHEMA cylinders was applied using 100°C hot air supplied by a TENMA 21-10125 rework station (Tokyo, Japan). The hot air gun was positioned approximately 1 cm from the sample surface and held for 10-20 seconds.

3.3.3 Dimensional Measurements

The samples were measured using Mitutoyo digimatic calipers 0-150 mm (Mitutoyo, Sakado, Japan).

3.3.4 Compression Test

Six layer polyHEMA cylinders were tested in compression using a H25KS Tinius Olsen Ltd. (Surrey, UK) testing machine with a 25 kN load cell. The cylinders were initially trimmed at each end to create parallel surfaces. The crosshead speed was 2 mm/minute and samples were tested to failure.

3.4 Statistical Methods

Collected data were processed and formatted using Microsoft Excel 2016. Statistical data analysis was performed using GraphPad Prism 6®. One-way analysis of variance (ANOVA) were performed using a Tukey’s HSD post-hoc test, two-way ANOVAs were performed when possible to determine variation between data sets.
4 Results

4.1 Curing of Single Layers

4.1.1 Morphology

Figure 4 shows the polyHEMA discs from formulations A – C with 1 and 4 minutes exposure times. After 1 minute exposure the polyHEMA discs from formulations A and C have strong yellow colour. The discs all had a meniscus, with some material failing to cover the PTFE mould surface (denoted by the arrows in figure 4A). Figure 4B shows that apart from those samples where material coverage was incomplete the diameter of the samples was consistent and not significantly affected by exposure time.

4.2 FTIR and Degree of Conversion

Figure 5A shows the ATR-FTIR spectra from single layer specimens of formulation A following exposure for 1-10 minutes, indicating that 1 minute of exposure was sufficient for the radical polymerisation reaction to take place. Results from figure 5B indicate no significant differences between the degree of conversion of HEMA monomer from the different formulations across all of the exposure times.
Figure 4: A) images of polyHEMA discs from formulations A-C following photopolymerisation with 1 and 4 minutes exposure (10 mm scale bar). Arrows denote incomplete coverage of mould surface B) Diameter of polyHEMA discs. Bars shows the mean ± the standard deviation.
Figure 5: A) ATR-FTIR spectra of formulation A before and after 1 minute exposure. Narrow scan from 1550 – 1800 cm$^{-1}$ showing aliphatic C-C (1710 cm$^{-1}$) and aromatic C=C (1638 cm$^{-1}$) vibrational modes. B) The degree of HEMA monomer conversion from formulations A-C. The bars represent the mean ± the standard deviation (n = 3).
4.3 Multiple layer curing

4.4 Morphology

Figure 6A shows that the multi-layer polyHEMA cylinders retained the meniscus throughout the addition of further layers. Superficial heating of the cut surface of the polyHEMA plugs revealed curved lined features correlating to the layer interfaces (figure 6B).

Figure 6C shows that the cylinders were broadly consistent in diameter, although the single layer specimens were on average around 2% smaller in diameter than the multi-layer specimens. The sequential weight gains were broadly as would be expected, as were most of the height gains, apart from layers 4 and 5 where some levelling out of the meniscus seems to occur. Note that the height of layer 1 is misleading: in all cases the height measurement was to the top of the meniscus.

4.5 Degree of Conversion

Figure 7 (left) shows ATR-FTIR analysis of the base layer degree of conversion following sequential layer addition, and indicates no significant difference in degree of conversion of the polymer on the base layer for samples of different heights. In addition, ATR-FTIR of the cross-sectioned samples, figure 7 (right), shows that the degree of conversion through the layers remained consistent throughout, with no significant differences in DC.
4.6 Mechanical Properties

Compression testing with 6-layer samples gave an average modulus of 204 MPa (min 184 MPa, max 240 MPa), and an average compressive strength of 82 MPa (min 69 MPa, max 92 MPa).
Figure 6: A) Images of polyHEMA cylinders with 1–6 layers (10 mm scale bar). B) Stereomicroscope images of sectioned 6-layer polyHEMA cylinders following superficial heat treatment. C) Average diameter, edge height and weight of polyHEMA cylinders per layer. Dashed grid represents expected values per layer. Bars shows the mean ± the standard deviation (n = 3).
Figure 7: Base layer DC following sequential layer-by-layer exposure (left) and cross-sectional DC within the polyHEMA cylinders (right). Bars show the mean ± the standard deviation (n = 3).

5 Discussion

5.1 Effectiveness of the Processing Route in Curing HEMA

The curing of single layers resulted in some incomplete surface coverage, which remained inconsistent. This was most likely caused by poor wettability of the HEMA mixture on the PTFE substrate. However, the single layer experiments were valuable in showing that the 1 minute exposure time was sufficient to stimulate polymerisation of composition A. The sequential layer photopolymerisation processing route produced solid, robust polyHEMA cylinders which filled the model defects, with 6-layer cylinders produced in less than 10 minutes. The average degree of conversion for the multi-layer specimens was between 50% and 60%. The degree of conversion achieved was typical of blue light cured methacrylate based dental filler materials (for example Galvao et al.)
(2013)\textsuperscript{14} quote 55% for PMMA processed using conventional dental curing equipment; and Marovic et al. (2013)\textsuperscript{15} quote around 60% for a range of methacrylate based materials), so the processing route is considered to have achieved a DC broadly equivalent to that achieved in commercial light cured materials. We consider that a useful volume of material could be delivered and polymerised in-situ at a rate which is clinically practical, and so the approach is considered to have clinical promise.

5.2 Potential for Clinical Application

HEMA was used within this study as a model material with which to perform the proof of concept study – it does not have the biological properties for clinical application in a musculoskeletal application. In order for the approach to be viable for an orthopaedic application, the process would require the use of materials which would have in-vivo properties relevant to the musculoskeletal system. However, there is a significant body of work on photocurable materials which could have clinical application. Table 3 summarises materials which have potential to be applied to the musculoskeletal system using the arthroscopic approach outlined in this paper, and includes modified HEMA systems which could have potential alongside a range of other materials. For the most part these materials are not yet commercially available, but there is clear potential for an approach like the one outlined in this paper to be adopted for their use. Indeed several photocurable monomer systems have been used in additive manufacturing of cell – hydrogel constructs outlined in an excellent review by Melchels et al (2012)\textsuperscript{16}. Whilst the light curing kinetics will vary from material system to material system the rate at which the model plugs could be made within the proof of concept study gives confidence that delivery and cure in-situ of a wider range of materials within clinically relevant timescales will be possible. There is also the potential to reinforce the polymers
with a nano-scale bioceramic, and with an appropriate material delivery system functionally gradient composites could be created. The overall material system could be inert and biocompatible, designed to stay as deposited, or bioactive, designed to resorb over time and be replaced with natural tissue, and table 3 identifies both inert and bioactive materials.
<table>
<thead>
<tr>
<th>Category</th>
<th>Material/Reference</th>
<th>Targeted tissue</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synthetic polymers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polyurethanes(^{17})</td>
<td>Soft tissue</td>
<td>Polyurethane incorporating hydrolysable soft segments such as PCL or polypropylene glycol: <em>In-vivo</em> tested – 6 mm x 2 mm cylindrical discs subcutaneous implantation Wistar rats. <em>In-vivo</em> tested – 1 mL injected intramuscular injection dorsum Wistar rats.</td>
<td></td>
</tr>
<tr>
<td>Polylactic acid (PLA)(^{18,18})</td>
<td>Hard/ soft tissue Bone and heart</td>
<td>Ethylene glycol – lactic acid oligomer (2EG10LA): Critical size defect model Sprague-Dawley rats 8 mm defect Poly(TMC-DLLA): <em>In-vivo</em> assessment cardiomyocytes.</td>
<td></td>
</tr>
<tr>
<td>Polyhydroxyalkanoates (PHB)(^{15})</td>
<td>Hard/ soft tissue</td>
<td>PHB-co-hydroxylvalerate and HEMA membranes: No <em>in-vitro cell</em> / <em>in-vivo</em> testing</td>
<td></td>
</tr>
<tr>
<td>Polyethers(^{20})</td>
<td>Soft tissue</td>
<td>A number of polyethers such as poly(ethylene glycol) (PEG) are used to as part of oligomers and triblock copolymers. PCL-b-PEG-b-PCL: <em>In-vitro</em> assessment for adherence of fibroblasts.</td>
<td></td>
</tr>
<tr>
<td>Polycaprolactone (PCL)(^{17,21,22})</td>
<td>Soft tissue</td>
<td>PCL-b-PEG-b-PCL: <em>In-vitro</em> assessment for adherence of fibroblasts.</td>
<td></td>
</tr>
<tr>
<td>Poly(propylene fumarate) (PPF)(^{12,24})</td>
<td>Hard tissue Bone</td>
<td>PFF: 3D printed structures assessed for 112 days <em>in-vitro</em> with fibroblasts PFF/HEMA/Bioglass: 2D <em>in-vitro</em> assessment using human malignant melanoma cells. Bone adhesion mechanical tests.</td>
<td></td>
</tr>
<tr>
<td>Polylactides (PLA)(^{26})</td>
<td>Soft tissue Bone</td>
<td>Poly(6-aminoethyl propylene phosphate) (PPE) modified with acylated PEG (PPE-PEG): <em>In-vitro</em>: MSC 90%+ viability to monomer (max 10 mg/mL). MSC encapsulated in 8 mm diameter cylinders with 150 μL monomer solution (~3 mm height).</td>
<td></td>
</tr>
<tr>
<td>Polyanhydrides(^{16,27})</td>
<td>Hard/ soft tissue Bone</td>
<td>Poly(sebacic anhydride): <em>In-vivo</em> tested (4 days)– material was filled into 2 mm drilled tibia defect in Sprague-Dawley rats. New collagen and blood vessel formation observed around the implant site. Hydroxyapatite nanoparticle filled polyanhydride – no <em>in-vitro cell</em> / <em>in-vivo</em> testing.</td>
<td></td>
</tr>
<tr>
<td>Poly(ethylene oxide) (PEO)(^{28,29})</td>
<td>Soft tissue</td>
<td>HEMA and diethylene glycol dimethacrylate: No <em>in-vitro</em> study. HEMA grafted with polyamidoamine: <em>In-vitro</em> assessment encapsulating human MSC in a 1 cm diameter 3 mm height.</td>
<td></td>
</tr>
<tr>
<td><strong>Natural polymers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alginate(^{31})</td>
<td>Soft tissue</td>
<td>Alginate methacrylate: No <em>in-vitro</em> assessment.</td>
<td></td>
</tr>
<tr>
<td>Hyaluronic acid(^{29,31})</td>
<td>Soft tissue</td>
<td>Hyaluronan methacrylate: No <em>in-vitro</em> assessment.</td>
<td></td>
</tr>
<tr>
<td>Gelatin(^{32,33,34,35})</td>
<td>Soft tissue</td>
<td>Gelatin methacrylate (GelMA): <em>In-vitro</em>: 5 mm diameter cylinder with 2 mm thickness) <em>in-vivo</em>: C57BL/6j mice 1 mL injected subcutaneously.</td>
<td></td>
</tr>
<tr>
<td>Pullulan(^{36})</td>
<td>Soft tissue</td>
<td>Pullulan methacrylate. <em>In-vitro</em> assessment: Encapsulation of NIH 3T3 fibroblasts, HepG2 liver cells and endothelial cells assessed for viability.</td>
<td></td>
</tr>
<tr>
<td>Chitosan(^{3})</td>
<td>Soft tissue</td>
<td>Methacrylated glycol chitosan. <em>In-vitro</em> assessment: Viability study using chondrocytes – investigated formulation cytotoxicity and influence of irradiation on encapsulated cells. <em>In-vivo</em> assessment: Osteochondral defect explant model - 4 mm diameter in New Zealand white rabbit’s knees cultured for 14 days.</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3:** Summary of potential injectable photocurable biomaterials for bone and cartilage repair.
For a range of reasons, we consider that the use of a membrane to isolate the volume within the body where the plug would be delivered would be required. This would avoid the ingress of blood into the build volume, and would mean that monomers would not leach into the surrounding tissue prior to being polymerised. As a result of the feasibility study a third reason can be identified: the membrane and implant materials should be chosen to avoid the formation of a meniscus. Meniscus formation is controlled by the wettability of the wall material by the contained liquid, and so engineering the surface properties of the membrane offers a way of controlling the overall shape of the implant. The choice of membrane material would clearly also depend upon whether an inert or bioactive implant was being developed. For an inert material a poly(methyl methacrylate) membrane would offer good levels of biocompatibility, whereas for a bioactive implant there are a range of possible membranes to support tissue regeneration.

6 Conclusions

In-vivo additive manufacture using a minimally invasive approach offers an attractive route to the production of implants for the musculoskeletal system, and we have demonstrated proof of principle for a system based on light curable biomaterials. A simple model system has been developed in order to build plugs of appropriate dimensions suitable for chemical and mechanical characterisation. HEMA, used as a model material, demonstrated that appropriate volumes of material could be delivered within clinically relevant timescales and effectively polymerised in-situ, with minimal influence of the sequential layer manufacture process on the degree of conversion. A wide range of light curable biomaterials, with potential for application across the musculoskeletal system using this processing route, are being developed.
7 Acknowledgments

This work reported in this paper was funded by the EPSRC Centre for Innovative Manufacture in Medical Devices (MeDe Innovation; EP/K029592).

8 References


30. Smeds, K. A. & Grinstaff, M. W. Photocrosslinkable polysaccharides for in situ


